Back to Agenda
IMI PREFER: Patient Perspective in Benefit-Risk Assessments during the Medical Product Life Cycle
Session Chair(s)
Conny Berlin, MS
IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology, Novartis Pharma AG, Switzerland
Patient involvement in development of medicinal products is a topic rapidly evolving. However, how can patient preferences be elicited? Can it be used for regulatory decision making about benefits and risks of medicinal products? This session presents expectations, needs and concerns of different stakeholders and promising approaches how to address these.
Speaker(s)
Esther De Bekker-Grob
Associate Professor of Health Economics & Health Preferences, Erasmus School of , Erasmus University Rotterdam, Netherlands
Exploring and Eliciting Patient Preferences: Why, When and How
Isabelle Manneh-Vangramberen
Head of EU Health & Research Programmes, European Cancer Patient Coalition (ECPC), Belgium
Patients as Collaborators in Research
Sabine Haubenreisser, PHD, MSC
Principal Scientific Administrator, Stakeholders and Communication Division, European Medicines Agency, Netherlands
Patient Preference Studies in Regulatory Decisions: Opportunities and Challenges
Have an account?